Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 270 pages

Showing 201 - 250


lymphoma

Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

lymphoma

Bertrand Coiffier, MD, PhD, on Radiotherapy Plus R-CHOP in Localized Diffuse Large B-Cell Lymphoma

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393, “R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group,”...

leukemia
lymphoma

Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily...

lymphoma
myelodysplastic syndromes

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North...

lymphoma

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following...

lymphoma

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504, “Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association With CHOP in Patients With Peripheral T-Cell Lymphoma (PTCL)” presented by Jehan Dupuis, MD. Time: 1:53

lymphoma
survivorship
issues in oncology

Study Shows Inferior Outcomes for African American Pediatric Lymphoma Patients

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have published a study showing that African American pediatric patients with Hodgkin lymphoma have inferior overall survival compared with their white and Hispanic peers. The study, published ...

lymphoma
survivorship

Survivorship Symposium 2016: Study Finds That Less Than Half of Survivors of Hodgkin Lymphoma Received All Recommended Follow-up Care

According to the American Cancer Society’s 2014 Cancer Facts & Figures, Hodgkin lymphoma is diagnosed in about 800 adolescents and young adults each year. And while standard treatments for the cancer, including chemotherapy and radiation, are very effective in improving survival,...

lymphoma

Erratum

In the June 10 issue of The ASCO Post, the article, “Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma,” includes an error in an Expert Point of View box featuring an interview with Andrew D. Zelenetz, MD, PhD. Dr. Zelenetz is quoted as saying that at his...

lymphoma

City of Hope Receives $10 Million Gift to Launch Lymphoma Research and Treatment Center

A $10 million gift from Internet publishing entrepreneurs and philanthropists Emmet and Toni Stephenson and their daughter Tessa Stephenson Brand will fund the creation of the Toni Stephenson Lymphoma Center at City of Hope, Duarte, California, the cornerstone of the institution’s new Hematologic...

leukemia
lymphoma

The Leukemia & Lymphoma Society Surpasses $1 Billion Investment in Blood Cancer Research

The Leukemia & Lymphoma Society (LLS) has announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as the Society continues its 65-year pursuit of advancing breakthrough therapies, finding cures, and ensuring access to...

issues in oncology
lymphoma

The Power of Laughter

The following essay by Julie Vose, MD, MBA, FASCO, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories (May 2014), coedited by Stan Winokur, MD, and Vincent Coppola. The book is available on Amazon.com and thebigcasino.org.   When I met Cindy, she was...

lymphoma

Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research

Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...

hematologic malignancies
leukemia
lymphoma
lymphoma

ASH 2015: High Response Rates, Long-Term Remissions in Relapsed/Refractory Pediatric ALL, Lymphomas After CTL019 Immunotherapy

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over 1 year in 18 patients and over 2 years in nine...

leukemia
lymphoma
lymphoma

ASH 2015: Engineered Donor T Cells May Eradicate Progressive Disease After Stem Cell Transplant

A study (Abstract 99) to be reported today by Brudno et al at the 57th American Society of Hematology (ASH) Annual Meeting was the first clinical trial to use engineered donor immune cells to prevent progressive cancer after stem cell transplantation. The findings were presented at a...

kidney cancer
lung cancer
skin cancer
lymphoma
kidney cancer
head and neck cancer

Kidney Failure and Its Treatment May Impact Cancer Risk

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...

lymphoma

Researchers Link Immunosuppressive Mycophenolate Mofetil to Increased Risk of Central Nervous System Lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil to an increased risk of central nervous system lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, calcineurin inhibitors, given ...

hematologic malignancies
leukemia
lymphoma
issues in oncology

Half-Matched Bone Marrow Transplant Recipients May Tolerate Transplantation Just as Well as Fully Matched Recipients

Bone marrow transplantation is a lifesaving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, most likely a sibling, with a perfect match to the patient in order to minimize the chance of...

lymphoma

Brentuximab Vedotin Effective, Safe in Elderly Hodgkin Lymphoma Patients Who Cannot Tolerate Standard Chemotherapy

A study published by Forero-Torres et al in Blood reported that brentuximab vedotin (Adcetris) is an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are unfit for chemotherapy.  Ineligibility for Chemotherapy Although standard chemotherapy can...

lymphoma

ECC 2015: Living Conditions and Gender Appear to Affect Incidence of Hodgkin Lymphoma

Living in overcrowded conditions appears to protect children and young adults against developing a particular type of Hodgkin lymphoma. This protective effect seems to suggest that infections earlier in life may stimulate the immune system to deal with future infections and cancerous cells more...

lymphoma

FDA Grants Regular Approval to Brentuximab Vedotin as Post-Transplant Consolidation Therapy for High-Risk Classical Hodgkin Lymphoma

The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris) as post–autologous hematopoietic stem cell transplantation consolidation treatment for patients with classical Hodgkin lymphoma at high risk of relapse or progression, Seattle Genetics has announced. The...

lymphoma

Malaria-Causing Parasite May Contribute to Development of Burkitt Lymphoma

In an equatorial African region known as the “lymphoma belt,” children are ten times more likely than in other parts of the world to develop Burkitt lymphoma. This area is also plagued by high rates of malaria, and scientists have spent the past 50 years trying to understand how the two ...

hematologic malignancies
lymphoma

Investigational Topical Gel Is Safe and Effective in Patients With Cutaneous T-Cell Lymphoma, Phase I Trial Shows

Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...

lymphoma
issues in oncology

Trial Shows Molecular Subtypes of Diffuse Large B-Cell Lymphoma React Differently to Ibrutinib

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study was published by Wilson et al in Nature Medicine. In this phase II...

cns cancers
gynecologic cancers
colorectal cancer
leukemia
lymphoma
skin cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers

A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...

leukemia
lymphoma
survivorship

ASCO 2015: Reduction in Late Mortality Among Childhood Cancer Survivors Linked to Improvements in Cancer Care

Survivors of childhood cancer in recent eras have shown a significant reduction in late mortality, and “for the first time, we have been able to attribute that to fewer deaths from treatment-related causes or fewer deaths from late effects of the primary therapy,” Gregory T....

lymphoma

ASCO 2015: Obinutuzumab Doubles Progression-Free Survival in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard bendamustine (Treanda) chemotherapy and then following that with single-agent obinutuzumab maintenance therapy “resulted in a statistically significant, but more importantly, a clinically meaningful increase in...

hematologic malignancies
leukemia
multiple myeloma
lymphoma

Study Links Paternal Age to Child’s Risk of Developing Blood and Immune System Cancer in Adulthood

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, published by Teras et al in the American Journal of Epidemiology, found no association between having an older mother and these...

hepatobiliary cancer
lymphoma
prostate cancer
kidney cancer

Cancer Rates Significantly Increased Among Patients With Hepatitis C

Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...

lymphoma

International Lymphoma Radiation Oncology Group Issues Treatment Guidelines for Pediatric Hodgkin Lymphoma

The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of three-dimensional (3D) computed tomography (CT)–based radiation therapy planning and volumetric image guidance, specifically to more effectively treat pediatric Hodgkin lymphoma. The...

lymphoma

Phase III Study Shows Significant Benefit of Obinutuzumab in Refractory Indolent Non-Hodgkin Lymphoma

In a preplanned interim analysis of the phase III GADOLIN trial, obinutuzumab (Gazyva) plus bendamustine (Trenada) followed by obinutuzumab alone was found to significantly improve progression-free survival compared to bendamustine alone in patients with indolent, refractory non-Hodgkin lymphoma....

leukemia
lymphoma
issues in oncology

Study Shows Immunosuppressives, Chemotherapy May Reactivate Hepatitis B

Individuals previously infected with the hepatitis B virus (HBV) that receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the virus, according to a report published by Di Bisceglie et al in Hepatology. Reactivation of HBV can be fatal, and researchers suggest routine...

lymphoma

FDA Approves New Indication for Ibrutinib in Waldenström's Macroglobulinemia

The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s...

lymphoma

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Soligenix’s synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation is reserved for drugs that demonstrate the potential to address an...

lymphoma

FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...

lymphoma

ASTRO: Radiation Therapy Improves Survival in Patients With Early-Stage Hodgkin Lymphoma

Patients with stage I and II Hodgkin lymphoma who received consolidated radiation experienced improved 10-year survival rates, according to research presented at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting (Abstract CT-08). The 10-year survival rate for patients who...

lymphoma
survivorship

Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma

Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...

lymphoma

FDA Grants Orphan Drug Designation to Mocetinostat for Diffuse Large B-Cell Lymphoma

The U.S. Food and Drug Administration has granted Orphan Drug Designation to Mirati Therapeutics’ mocetinostat, a spectrum-selective HDAC inhibitor, for diffuse large B-cell lymphoma. In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome....

hematologic malignancies
leukemia
lymphoma

FDA Approves Idelalisib for Three Types of Blood Cancers

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for the treatment of patients with three types of blood cancers. Idelalisib is being granted traditional approval to treat patients with relapsed chronic lymphocytic leukemia (CLL). Used in combination with rituximab...

lymphoma
lymphoma

FDA Approves Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to belinostat (Beleodaq), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). “This is...

hematologic malignancies
lymphoma

Early Evidence Suggests Proton Therapy May Offer Safe, Long-Term Treatment for Hodgkin Lymphoma

Despite some success in treating patients with Hodgkin lymphoma, many patients may experience late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. A study by Hoppe et al from the University of Florida Proton Therapy Institute...

lymphoma

ASCO 2014: Bortezomib Combination Significantly Improves Progression-Free Survival in Newly Diagnosed Mantle Cell Lymphoma

An international, randomized phase III study found that replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved outcomes in newly diagnosed patients with mantle cell lymphoma who were...

lymphoma

FDA Accepts New Drug Application for Idelalisib in Refractory Indolent Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for idelalisib, a targeted, oral inhibitor of PI3K-delta, for the treatment of refractory indolent non-Hodgkin lymphoma (NHL). The FDA has granted a standard review for the NDA, with a target review date of...

leukemia
lymphoma

FDA Approves Revised Prescribing Information for Ponatinib, Authorizes Resumption of Drug Sales and Distribution

The U.S. Food and Drug Administration (FDA) has approved revised prescribing information and a Risk Evaluation and Mitigation Strategy (REMS) for ponatinib (Iclusig) that allows immediate resumption of its marketing and commercial distribution. The prescribing information includes a revised...

lymphoma

ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma

The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...

lymphoma

FDA Approves Ibrutinib for Mantle Cell Lymphoma

The U.S. Food and Drug Administration today approved ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma, an aggressive B-cell lymphoma that represents about 6% of all non-Hodgkin lymphoma cases in the United States. The drug, a Bruton’s tyrosine kinase inhibitor, is ...

lymphoma

Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...

lymphoma

FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma

Ceptaris Therapeutics, Inc, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug mechlorethamine gel (Valchlor) for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who...

lymphoma

Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic ...

lymphoma

New Research Suggests Restricting Calories May Improve Response to Cancer Treatment

New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and efficacy of targeted cancer therapies. Study results were published online...

Advertisement

Advertisement



Advertisement